NCT04162769

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled 16-Week Study (With a 52-Week Open-Label Extension) to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 140 (actual)
• Sponsor: Arena Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderate-to-severe atopic dermatitis (AD).

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Etrasimod 1 mg	Etrasimod 1 mg tablet taken by mouth, once daily
DRUG	Etrasimod 2 mg	Etrasimod 2 mg tablet taken by mouth, once daily.
DRUG	Etrasimod matching placebo	Etrasimod matching placebo tablet by mouth, once daily.

Timeline

• Start date: 2019-10-04
• Primary completion: 2020-09-09
• Completion: 2021-10-11
• First posted: 2019-11-14
• Last updated: 2022-11-04
• Results posted: 2022-11-04

Locations

38 sites across 3 countries: United States, Australia, Canada

Regulatory

• FDA-regulated drug study